26791-73-1
基本信息
苍耳亭对照品
苍耳亭(反式)
苍耳亭(标准品)
(3aR)-3-Methylene-7β-methyl-6-(3-oxo-1-butenyl)-3,3aα,4,7,8,8aβ-hexahydro-2H-cyclohepta[b]furan-2-one
(3aR)-3,3aα,4,7,8,8aβ-Hexahydro-7β-methyl-3-methylene-6-(3-oxo-1-butenyl)-2H-cyclohepta[b]furan-2-one
(3aR,7S,8aS)-7-methyl-3-methylidene-6-[(E)-3-oxobut-1-enyl]-4,7,8,8a-tetrahydro-3aH-cyclohepta[b]furan-2-one
2H-Cyclohepta[b]furan-2-one,3,3a,4,7,8,8a-hexahydro-7-Methyl-3-Methylene-6-(3-oxo-1-buten-1-yl)-,(3aR,7S,8aS)-
(3aR,7S,8aS)-7-methyl-3-methylidene-6-[(1E)-3-oxobut-1-en-1-yl]-3,3a,4,7,8,8a-hexahydro-2H-cyclohepta[b]furan-2-one
2H-Cyclohepta[b]furan-2-one, 3,3a,4,7,8,8a-hexahydro-7-methyl-3-methylene-6-[(1E)-3-oxo-1-buten-1-yl]-, (3aR,7S,8aS)-
物理化学性质
| 外观性状 | 来源于菊科植物苍耳Xanthium sibiricum干燥成熟带总苞的果实 |
| 熔点 | 114.5-115° |
| 比旋光度 | D30 -20° (ethanol) |
| 储存条件 | Sealed in dry,2-8°C |
| 沸点 | 444.3±45.0 °C(Predicted) |
| 密度 | 1.10±0.1 g/cm3(Predicted) |
安全数据
| 危险性符号(GHS) |  GHS07 |
| 警示词 | 警告 |
| 危险性描述 | H302-H315-H319 |
| 防范说明 | P501-P270-P264-P280-P302+P352-P337+P313-P305+P351+P338-P362+P364-P332+P313-P301+P312+P330 |
应用领域
药理药效:抗菌、消炎作用。
常见问题列表
苍耳亭（标准品）用于含量测定、鉴别、药理实验、活性筛选等。
苍耳子的毒性源于其富含的倍半帖内酯类化合物,这类 成分常含有α,β不饱和y内酯结构,是其生物活性的一个主要基团。研究表明，从苍耳属(Xanthium L.)植物(如苍耳 子)中提取得到的倍半黏内酯化合物苍耳亭( Xanthatin),在 体内外实验中均显示出较强的抗肿瘤活性,其对非小细胞肺 癌的生长存在显著的抑制作用,且对正常肺上皮细胞生长影响较小。
IC50: apoptosis; 3.8 μM (VEGFR2 kinase); 2.63 µg/mL ( T. b. brucei )
Xanthatin is against T. b. brucei with an IC 50 value of 2.63 µg/mL and exhibits weak irreversible inhibition of parasite specific trypanothione reductase.Xanthatin (0-40 μM; 24 hours) has obscure inhibition effect on the proliferation of HUVEC in the absence of VEGF.Xanthatin (5-40 μM; 24 hours) inhibits breast cancer cell proliferation in a dose responsive manner. Xanthatin inhibits HCC1937, MDA-MB-415, SK-BR-3, MCF-7 and MDA-MB-231 with IC 50 values of 81 μM, 31 μM, 38 μM, 30 μM, and 17 μM, respectively.Xanthatin (0-10 μM; 24 hours) dose dependently suppresses the phosphorylation of STAT3 (Ser727), at the same time, it also results in a rapid dephosphorylation of down-stream kinases of STAT3, including PI3K and Akt, including PI3K (p-PI3K p85 tyr458 ) and Akt.
Cell Proliferation Assay
| Cell Line: | HUVEC cells |
| Concentration: | 0 μM, 5 μM, 10 μM, 15 μM, 20 μM, 30 μM, 40 μM |
| Incubation Time: | 24 hours |
| Result: | Inhibited cell growth from dose 10 μM in the presence of vEGF. |
Cell Viability Assay
| Cell Line: | HCC1937, MDA-MB-415, SK-BR-3, MCF-7 and MDA-MB-231 cells |
| Concentration: | 5, 10, 15, 20, 30, and 40 μM |
| Incubation Time: | 24 hours |
| Result: | Inhibited breast cancer cell growth. |
Western Blot Analysis
| Cell Line: | HUVEC cells |
| Concentration: | 0, 3, and 10 μM |
| Incubation Time: | 24 hours |
| Result: | Inhibited VEGFR2 downstream signaling pathways and blocked VEGF-induced STAT3 activation in HUVEC. |
Xanthatin (intragastric administration; 20 mg/kg; once daily; 25 days) leads to significant inhibition of tumor volume. And this compound is well-tolerated and exhibits no significant difference in weight compares to the vehicle group.
| Animal Model: | Transplanted MDA-MB-231 cells into mice and constucted human breast cancer xenograft mouse model |
| Dosage: | 20 mg/kg; once daily; 25 days |
| Administration: | Intragastric administration |
| Result: | Supressed tumor growth and tumor angiogenesis in vivo. |